Comparative Pharmacology
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus MPI INDIUM DTPA IN 111.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDIUM IN 111 PENTETREOTIDE KIT versus MPI INDIUM DTPA IN 111.
INDIUM IN-111 PENTETREOTIDE KIT vs MPI INDIUM DTPA IN 111
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indium In-111 pentetreotide binds to somatostatin receptors, particularly subtypes 2 and 5, allowing scintigraphic localization of primary and metastatic neuroendocrine tumors bearing these receptors.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
111 MBq (3 mCi) indium In-111 pentetreotide administered intravenously over 1 minute; single dose for planar and SPECT imaging.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal half-life approximately 24 hours (range 22-26 hours), allowing imaging up to 24-48 hours post-injection
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Renal: 80-90% unchanged within 24 hours; Fecal: 5-10%
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical